Stock comparison
IDEXX Laboratories
MannKind
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
MNKD
MannKind
Market cap
$1.04B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | MNKD | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 43D | IDXX |
| Benjamin Graham | 80A | 23F | IDXX |
| Philip Fisher | 75B | 59C | IDXX |
| Peter Lynch | 71B | 60C | IDXX |
| Joel Greenblatt | 83C | 40D | IDXX |
| Charlie Munger | 87A | 48D | IDXX |
| Terry Smith | 84A | 52D | IDXX |
Side-by-side metrics
| Metric | IDXX | MNKD |
|---|---|---|
| Market cap | $44.12B | $1.04B |
| P/E (TTM) | 39.0x | - |
| EV/EBIT | 31.6x | 36.6x |
| ROIC (TTM) | 40.66% | 1.8% |
| Gross margin | 62.05% | 75.96% |
| Net margin | 24.63% | -6.63% |
| Revenue CAGR 5y | 7.56% | 46.65% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Net margin24.63%vs -6.63%+127%
- Market cap$44.12Bvs $1.04B+98%
- ROIC (TTM)40.66%vs 1.8%+96%
- EV/EBIT31.6xvs 36.6x+14%
MNKD leads on
- P/E (TTM)-vs 39.0x+190%
- Debt / Equity-vs 0.7x+109%
- Revenue CAGR 5y46.65%vs 7.56%+84%
- Gross margin75.96%vs 62.05%+18%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.